Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06415487 · ClinicalTrials.gov registry record · Phase 1
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
A Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, sponsored by Acepodia Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT06415487: Recruiting Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, sponsored by Acepodia Biotech.
NCT06415487 is a Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor that is actively recruiting participants, run by Acepodia Biotech. The registered enrollment target is 30 participants, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (84% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06415487, a Phase 1 study of Metastatic Solid Tumor and Locally Advanced Solid Tumor, is actively recruiting participants, sponsored by Acepodia Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG ACE2016
Study Locations (9)
California
- University of California San Diego - San Diego
Colorado
- SCRI Denver Drug Development Unit - Denver
Tennessee
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Nashville
Texas
- Texas Oncology - Dallas
Beitou District
- Taipei Veterans General Hospital - Taipei
Guishan District
- Chang Gung Medical Foundation Linkou - Taoyuan
Zhonghe District
- Taipei Medical University-Shuang Ho Hospital - New Taipei City
Zhongshan District
- Mackay Memorial Hospital Taipei - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2027-03-27 |
| Phase | Phase 1 |
What NCT06415487 shows while recruiting
NCT06415487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT06415487 lists 9 locations in 9 states (California, Colorado, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06415487 about?
NCT06415487 is a clinical study titled "ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)". ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, fir...
What is the current status of trial NCT06415487?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-08-22. Estimated completion is 2027-03-27.
What conditions does trial NCT06415487 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor, Locally Advanced Solid Tumor.
What interventions are being tested in trial NCT06415487?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), ACE2016 (DRUG).
Who is sponsoring clinical trial NCT06415487?
This trial is sponsored by Acepodia Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06415487 being conducted?
This trial has 9 study locations across California, Colorado, Tennessee, Texas, Beitou District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06415487's enrollment target sits among peer trials
30 48th of 52 higher than 3 of 52 other Metastatic Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI